RCKT vs. RCUS, DRNA, AUPH, YMAB, HRTX, ASND, LEGN, CERE, VKTX, and ITCI
Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Arcus Biosciences (RCUS), Dicerna Pharmaceuticals (DRNA), Aurinia Pharmaceuticals (AUPH), Y-mAbs Therapeutics (YMAB), Heron Therapeutics (HRTX), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Viking Therapeutics (VKTX), and Intra-Cellular Therapies (ITCI). These companies are all part of the "medical" sector.
Rocket Pharmaceuticals (NASDAQ:RCKT) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.
Rocket Pharmaceuticals has higher earnings, but lower revenue than Arcus Biosciences. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Rocket Pharmaceuticals had 11 more articles in the media than Arcus Biosciences. MarketBeat recorded 15 mentions for Rocket Pharmaceuticals and 4 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 0.95 beat Rocket Pharmaceuticals' score of 0.13 indicating that Arcus Biosciences is being referred to more favorably in the news media.
Rocket Pharmaceuticals has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.
Rocket Pharmaceuticals received 189 more outperform votes than Arcus Biosciences when rated by MarketBeat users. Likewise, 72.18% of users gave Rocket Pharmaceuticals an outperform vote while only 64.54% of users gave Arcus Biosciences an outperform vote.
Rocket Pharmaceuticals presently has a consensus target price of $52.13, suggesting a potential upside of 144.49%. Arcus Biosciences has a consensus target price of $41.25, suggesting a potential upside of 173.54%. Given Arcus Biosciences' higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than Rocket Pharmaceuticals.
98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 31.1% of Rocket Pharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Rocket Pharmaceuticals has a net margin of 0.00% compared to Arcus Biosciences' net margin of -97.47%. Arcus Biosciences' return on equity of -40.98% beat Rocket Pharmaceuticals' return on equity.
Summary
Rocket Pharmaceuticals beats Arcus Biosciences on 11 of the 17 factors compared between the two stocks.
Get Rocket Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rocket Pharmaceuticals Competitors List
Related Companies and Tools
